Recon: FDA approves BeiGene's Brukinsa for rare blood cancer; House Committees request records from FDA's Aduhelm review
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy